Leiden based ProQR invented the idea of using RNA oligonucleotides to induce ADAR to edit RNA over 10 years ago - the first programs are scheduled to enter the clinic soon

blonca9
Oct 8, 2024
1 min read

Founder and CEO Daniel de Boer describes ProQR's history in Leiden and why it is an ideal spot for a biotech company to be based. Plus, he walks us through the company's RNA editing approach and updates us on the status of its programs, two of which are guided to enter the clinic in late 2024/early 2025.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Leiden based ProQR invented the idea of using RNA oligonucleotides to induce ADAR to edit RNA over 10 years ago - the first programs are scheduled to enter the clinic soon

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight